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Manuscript
Stimulation of airway β2-adrenoceptors (β2ADR) by short or long acting 
agonists (LABA) via the classical (canonical) G protein cyclic adenosine 
monophosphate (Gs-cAMP) signalling pathway results in bronchodilation and 
relief of asthma symptoms. However β2-agonists may also activate non 
canonical (Gs-cAMP independent) β-arrestin mediated pro-inflammatory 
signalling pathways via extracellular signal regulated kinases (ERK1/2)1.  In 
knockout mice β-arrestin-2 regulates the development of allergic asthma2. 
Chronic exposure to LABA causes adaptive down-regulation and uncoupling 
of β2ADR with associated sub-sensitivity of response and in some cases 
worse asthma control3 .  In the antigen driven mouse model, depletion of 
adrenaline the natural ligand for the β2ADR, prevented the development of 
asthma4.  Replacement of β2ADR signalling by administration of formoterol 
(LABA) restored the asthma phenotype, showing that agonist induced 
activation of β2ADR results in development of asthma4.  This suggests 
paradoxically that perhaps using an inverse agonist might be a better strategy 
in asthma management.  An inverse agonist is one which stabilises the 
inactive receptor conformation and blocks its constitutive activity, by switching 
off β2ADR signalling. 
β-antagonists are contra-indicated in patients with asthma even using β1 
selective agents, due to the effects of β2ADR blockade by promoting 
cholinergic transmission and bronchoconstriction, especially upon first dose 
exposure.  It would therefore seem counterintuitive to ever consider giving a 
non selective β-blocker such as nadolol as anti-asthma therapy. 
It has been proposed that switching off β2ADR (thereby lowering cAMP) with 
an inverse β2-agonist such as nadolol might paradoxically result in improved 
in airway AHR and associated control5.  This concept was supported by data 
from knockout mice devoid of β2ADR who when exposed to antigen did not 
develop airway hyper-responsiveness (AHR) or other cardinal inflammatory 
features of the asthma phenotype, while the same phenomenon also occurred 
with nadolol treatment in wild type mice expressing β2ADR6.  Moreover 
nadolol confers complimentary corticosteroid sparing anti-inflammatory 
activity in the mouse model7. 
It was subsequently shown in adrenaline depleted mice that  beneficial effect 
of β-blockers may be ligand specific in that exposure to propranolol but not 
nadolol resulted in the development of the asthma phenotype, while in wild 
type mice nadolol but not propranolol prevented the occurrence of asthma8. 
Thus nadolol reduces cAMP as a canonical inverse agonist and is a non 
canonical neutral antagonist on ERK1/21, resulting in an overall anti-asthmatic 
profile.  Propranolol acts as a so called biased ligand, stimulating ERK1/2 as a 
non canonical partial agonist while reducing cAMP as a canonical inverse 
agonist, resulting in a net null or pro-asthmatic profile1,8 (Figure). 
Studies in humans have revealed conflicting results with oral non selective β-
blockers.  Two open label studies with nadolol (10-40mg/day) in inhaled 
corticosteroid (ICS) naïve intermittent asthma showed improvements in 
methacholine AHR9,10.  One could cogently argue that using nadolol as 
monotherapy without ICS is not clinically relevant, in the same way that one 
would never give a LABA without ICS.  In contrast two placebo controlled 
trials with propranolol (20-80mg/day) in ICS treated persistent asthma showed 
no improvement in methacholine or histamine AHR or in other inflammatory 
markers11,12.  Furthermore the salutary effect of an increased ICS dose 
confirmed that there was further room for potential improvement with 
propranolol and no corticosteroid sparing activity12.  It is possible that the 
impact of concomitant ICS might have either nullified the effect of propranolol 
due to β2ADR up-regulation, or perhaps counteracted a putative pro-
inflammatory action of propranolol. 
In both of these studies11,12 there was a non significant 2-4% fall in pre-
challenge FEV1 after propranolol verses placebo, while reliever use, asthma 
control and quality of life were not significantly affected.  The effect of 
sequential nebulised salbutamol and ipratropium after challenge showed a 
significant 5% attenuation in FEV1 between propranolol and placebo, 
although full recovery back to baseline occurred by 30 minutes.  Hence it may 
be possible to overcome the competitive antagonism due to propranolol by 
using a higher dose of β2-agonist.  During initial propranolol dose titration, 
concomitant tiotropium prevented bronchoconstriction due to increased 
cholinergic transmission13.  Post hoc analysis showed that propranolol 
induced bronchoconstriction was greater in patients who expressed the 
arginine-16 β2ADR polymorphism14.  
A placebo controlled trial (ClinTrials.gov identifier:NCT 01804218) evaluating 
oral nadolol as monotherapy in mild ICS naïve asthma will complete in 2016.  
Assuming it shows attenuation of methacholine AHR, it would also need to 
exhibit anti-inflammatory activity comparable to low dose ICS.  An inhaled 
formulation of nadolol in development (Invion Ltd, Brisbane, Australia) might 
offer a superior therapeutic ratio as a consequence of higher lung levels along 
with lower systemic exposure due to its hydrophilicity. 
If it transpires that switching off β2ADR confers improvements in persistent 
asthma, then it will surely challenge current dogma and guidelines regarding 
continuous β2ADR stimulation with LABA. The concept of moving therapy 
from β-agonists to their antagonists has already been adopted by 
cardiologists in heart failure.  Perhaps it is now the turn of pulmonologists to 
start thinking along similar lines for the treatment of asthma. 
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Figure Legend 
Effects of β-blockers on canonical (Gs-cAMP) and non-canonical signalling 
(ERK1/2).  Nadolol acts as an inverse agonist (solid arrow) reducing cAMP 
and a neutral antagonist (dashed arrow) on ERK1/2. Propranolol acts as an 
inverse agonist (solid arrow) to reduce cAMP and as a partial agonist (dotted 
arrow) to stimulate ERK1/. 
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